$INSM
INSMED Inc Stock $insm

$insm Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000110465914036103 Filed on May 08, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.870M	$6.730M	$3.980M
YoY Change	4.38%	69.1%	57.31%
% of Gross Profit
Research & Development	$14.94M	$11.35M	$10.33M
YoY Change	22.22%	9.83%	118.06%
% of Gross Profit
Depreciation & Amortization	$170.0K	$167.0K	$148.0K
YoY Change	13.33%	12.84%	8.82%
% of Gross Profit
Operating Expenses	$22.82M	$18.08M	$14.31M
YoY Change	15.41%	26.35%	96.99%
Operating Profit	-$22.82M	-$18.08M	-$14.31M
YoY Change	175.92%	26.35%	96.99%
Interest Expense	$595.0K	$606.0K	$643.0K
YoY Change	-6.3%	-5.75%	32050.0%
% of Operating Profit
Other Income/Expense, Net	$175.0K	-$19.00K	$2.000K
YoY Change		-1050.0%	-80.0%
Pretax Income	-$23.22M	-$18.69M	-$14.90M
YoY Change	162.3%	25.42%	117.73%
Income Tax	$0.00	-$4.389M	-$1.221M
% Of Pretax Income
Net Earnings	-$23.22M	-$14.30M	-$13.68M
YoY Change	162.25%	4.55%	99.82%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$591.3K	-$364.4K	-$433.6K
COMMON SHARES
Basic Shares Outstanding	39.27M shares	39.24M shares	31.55M shares
Diluted Shares Outstanding	39.27M shares	39.24M shares	31.55M shares

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$82.70M	$101.3M	$81.60M
YoY Change	7.68%	24.14%	15.25%
Cash & Equivalents	$82.70M	$101.3M	$79.43M
Short-Term Investments
Other Short-Term Assets	$4.000M	$5.000M	$1.400M
YoY Change	122.22%	257.14%	600.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$86.70M	$106.2M	$83.03M
YoY Change	10.35%	27.92%	16.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.778M	$1.977M	$1.681M
YoY Change	151.47%	17.61%	-11.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$400.0K	$200.0K	$100.0K
YoY Change	300.0%	100.0%	0.0%
Total Long-Term Assets	$63.41M	$60.41M	$59.99M
YoY Change	5.4%	0.7%	-3.71%
TOTAL ASSETS
Total Short-Term Assets	$86.70M	$106.2M	$83.03M
Total Long-Term Assets	$63.41M	$60.41M	$59.99M
Total Assets	$150.1M	$166.6M	$143.0M
YoY Change	8.21%	16.5%	7.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.41M	$9.818M	$8.184M
YoY Change	44.39%	19.97%	182.21%
Accrued Expenses	$4.546M	$3.143M	$5.329M
YoY Change	42.6%	-41.02%	432.9%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.281M	$5.187M	$4.875M
YoY Change	-30.19%	6.4%	4775.0%
Total Short-Term Liabilities	$21.82M	$20.00M	$20.27M
YoY Change	20.53%	-1.35%	394.44%
LONG-TERM LIABILITIES
Long-Term Debt	$16.49M	$14.57M	$14.51M
YoY Change	10.74%	0.4%	14411.0%
Other Long-Term Liabilities	$300.0K	$300.0K	$600.0K
YoY Change	-40.0%	-50.0%	-33.33%
Total Long-Term Liabilities	$16.49M	$14.57M	$14.51M
YoY Change	10.74%	0.4%	1351.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.82M	$20.00M	$20.27M
Total Long-Term Liabilities	$16.49M	$14.57M	$14.51M
Total Liabilities	$38.56M	$34.88M	$35.41M
YoY Change	16.87%	-1.49%	594.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$429.1M	-$405.9M	-$349.2M
YoY Change		16.23%
Common Stock	$393.0K	$393.0K	$316.0K
YoY Change		24.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$111.5M	$131.7M	$107.6M
YoY Change
Total Liabilities & Shareholders Equity	$150.1M	$166.6M	$143.0M
YoY Change	8.21%	16.5%	7.29%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$23.22M	-$14.30M	-$13.68M
YoY Change	162.25%	4.55%	99.82%
Depreciation, Depletion And Amortization	$170.0K	$167.0K	$148.0K
YoY Change	13.33%	12.84%	8.82%
Cash From Operating Activities	-$17.93M	-$12.65M	-$11.21M
YoY Change	250.88%	12.85%	99.82%
INVESTING ACTIVITIES
Capital Expenditures	-$570.0K	$331.0K	$163.0K
YoY Change	72.73%	103.07%	146.97%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$570.0K	-$330.0K	-$160.0K
YoY Change	72.73%	106.25%	-101.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-60.00K	340.0K	20.00K
YoY Change	-110.0%	1600.0%	-166.67%
NET CHANGE
Cash From Operating Activities	-17.93M	-12.65M	-11.21M
Cash From Investing Activities	-570.0K	-330.0K	-160.0K
Cash From Financing Activities	-60.00K	340.0K	20.00K
Net Change In Cash	-18.56M	-12.64M	-11.35M
YoY Change	283.47%	11.37%	-257.64%
FREE CASH FLOW
Cash From Operating Activities	-$17.93M	-$12.65M	-$11.21M
Capital Expenditures	-$570.0K	$331.0K	$163.0K
Free Cash Flow	-$17.36M	-$12.98M	-$11.37M
YoY Change	263.18%	14.14%	100.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16338000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14298000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12649000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39240000	shares
CY2014Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39240000	shares
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-331000	USD
CY2014Q1	insm	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	1444000	USD
CY2014Q1	insm	Accrued Technical Operation Expenses AccruedTechnicalOperationExpenses	751000	USD
CY2014Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	764000	USD
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3143000	USD
CY2013Q4	insm	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	2484000	USD
CY2013Q4	insm	Accrued Technical Operation Expenses AccruedTechnicalOperationExpenses	1220000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	24000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13678000	USD
CY2013Q4	us-gaap	Interest Payable Current InterestPayableCurrent	159000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	18000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3905000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1812000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1977000	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4389000	USD
CY2014Q1	us-gaap	Secured Debt SecuredDebt	20000000	USD
CY2014Q1	insm	Additional Charge At End Of Term AdditionalChargeAtEndOfTerm	237000	USD
CY2014Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	179000	USD
CY2014Q1	insm	Unamortized Discount From Warrant UnamortizedDiscountFromWarrant	302000	USD
CY2014Q1	us-gaap	Debt Current DebtCurrent	5187000	USD
CY2014Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14569000	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	938000	USD
CY2014Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	7785000	USD
CY2014Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	8589000	USD
CY2014Q1	us-gaap	Long Term Debt LongTermDebt	20000000	USD
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39137679	shares
CY2013Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6900000	shares
CY2013Q3	insm	Common Stock Shares Exercise To Underwriters In Full Of Over Allotment Option CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption	900000	shares
CY2013Q3	us-gaap	Share Price SharePrice	10.40
CY2013Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67000000	USD
CY2013Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4700000	USD
CY2013Q4	insm	Number Of Equity Compensation Plans NumberOfEquityCompensationPlans	3	item
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3632996	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4229646	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	649050	shares
CY2014Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	52400	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3968337	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	617662	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.94
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.77
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	19.78
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.73
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	9.65
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.23
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y11M19D
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y11M16D
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y2M5D
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	39808000	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	37812000	USD
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	9148000	USD
CY2014Q1	insm	Unrecognized Tax Benefits Reserves UnrecognizedTaxBenefitsReserves	0	USD
CY2013Q4	insm	Unrecognized Tax Benefits Reserves UnrecognizedTaxBenefitsReserves	0	USD
CY2014Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2014Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	300000	USD
CY2013Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	945000	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	885000	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	474000	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	488000	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	460000	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	4190000	USD
CY2014Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	116163000	USD
CY2013Q4	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	58200000	USD
CY2013Q4	us-gaap	Other Assets OtherAssets	323000	USD
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	INSMED INC
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001104506
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39272501	shares
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	us-gaap	Assets Assets	166620000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	19998000	USD
CY2014Q1	us-gaap	Liabilities Liabilities	34882000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	131738000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	166620000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113894000	USD
CY2014Q1	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	58200000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2269000	USD
CY2013Q4	us-gaap	Assets Assets	176498000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5929000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2839000	USD
CY2013Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	307000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	129000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	64000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	33174000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16456000	USD
CY2013Q4	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	380000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3283000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	14309000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14309000	USD
CY2013Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	51000	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	643000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-161000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	29000	USD
CY2013Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	51000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	22000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-11348000	USD
CY2013Q1	us-gaap	Interest Paid InterestPaid	476000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90782000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	101251000	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	463000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	79434000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	391000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	534554000	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-405919000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-391621000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	143324000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	176498000	USD
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39268885	shares
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4389000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	337000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18079000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-12643000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	148000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	954000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	167000	USD
CY2013Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	118000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	18079000	USD
CY2013Q1	us-gaap	Accretion Expense AccretionExpense	49000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-18687000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2358000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10334000	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	393000	USD
CY2014Q1	us-gaap	Accretion Expense AccretionExpense	33000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3975000	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-14899000	USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1221000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	797000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1124000	USD
CY2013Q1	insm	Increase Decrease In Accrued Liabilities And Deferred Rent Credit IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit	1787000	USD
CY2013Q1	insm	Increase Decrease In Accrued Lease Expenses IncreaseDecreaseInAccruedLeaseExpenses	-64000	USD
CY2013Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-848000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-11209000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	163000	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	16000	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	353000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	331000	USD
CY2014Q1	insm	Increase Decrease In Accrued Lease Expenses IncreaseDecreaseInAccruedLeaseExpenses	-62000	USD
CY2014Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1468000	USD
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2000	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14298000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13678000	USD
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39137679	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39268885	shares
CY2013Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2014Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	3626000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	106209000	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4958000	USD
CY2014Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	17000	USD
CY2014Q1	insm	Increase Decrease In Accrued Liabilities And Deferred Rent Credit IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit	-770000	USD
CY2013Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1221000	USD
CY2014Q1	us-gaap	Other Assets OtherAssets	234000	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9818000	USD
CY2014Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1371000	USD
CY2014Q1	us-gaap	Accrued Rent Current AccruedRentCurrent	310000	USD
CY2014Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	121000	USD
CY2014Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	48000	USD
CY2014Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	5187000	USD
CY2014Q1	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	315000	USD
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	537264000	USD
CY2014Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	102000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2600000	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	606000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3889000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2013Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	2000	USD

Files In Submission

Name	View Source	Status
0001104659-14-036103-index-headers.html	Edgar Link	pending
0001104659-14-036103-index.html	Edgar Link	pending
0001104659-14-036103.txt	Edgar Link	pending
0001104659-14-036103-xbrl.zip	Edgar Link	pending
a14-9766_110q.htm	Edgar Link	pending
a14-9766_1ex10d1.htm	Edgar Link	pending
a14-9766_1ex10d2.htm	Edgar Link	pending
a14-9766_1ex10d3.htm	Edgar Link	pending
a14-9766_1ex31d1.htm	Edgar Link	pending
a14-9766_1ex31d2.htm	Edgar Link	pending
a14-9766_1ex32d1.htm	Edgar Link	pending
a14-9766_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
insm-20140331.xml	Edgar Link	completed
insm-20140331.xsd	Edgar Link	pending
insm-20140331_cal.xml	Edgar Link	unprocessable
insm-20140331_def.xml	Edgar Link	unprocessable
insm-20140331_lab.xml	Edgar Link	unprocessable
insm-20140331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INSM
INSMED Inc Stock $insm

2014 Q2 Form 10-Q Financial Statement

#000110465914036103 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSM INSMED Inc Stock $insm

2014 Q2 Form 10-Q Financial Statement

#000110465914036103 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSM
INSMED Inc Stock $insm